Germline Polymorphisms in EGFR and Survival in Patients With Lung Cancer Receiving Gefitinib

    loading  Checking for direct PDF access through Ovid

Abstract

The purpose of this study was to evaluate associations between germline epidermal growth factor receptor (EGFR) variants involved in transcriptional regulation and overall survival in white patients with non-small-cell lung cancer (NSCLC) treated with the EGFR tyrosine kinase inhibitor, gefitinib. Of 175 consecutive patients treated with oral gefitinib (250mg/day), 170 (median age: 67 years; 72% men) were evaluable for genotyping and survival. Fifty-five patients (33%) had stable disease and 17 (10%) had an objective response. The most common of four haplotypes was G-C (EGFR*1) at theEGFR- 216G>T and -191C>A loci (frequency, 0.45). After adjusting for performance status, previous platinum-containing chemotherapy and occurrence of skin rash or diarrhea during the first treatment cycle in patients with performance status 0 or 1 (N=139), the absence ofEGFR*1was associated with significantly better survival (hazard ratio: 0.54; 95% confidence interval: 0.32-0.91;P=0.015). The results may help identify patients with NSCLC who can benefit from gefitinib treatment.

Related Topics

    loading  Loading Related Articles